0000000001264845

AUTHOR

Katia Cagossi

showing 5 related works from this author

Metronomic Chemotherapy (mCHT) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): When Care Objectives Meet Patients’ Need. Preliminary Results …

2017

Oncologymedicine.medical_specialtybusiness.industryInternal medicineAdvanced breastmedicineCancerSurgeryGeneral Medicinebusinessmedicine.diseaseMetronomic ChemotherapyMetronomic Chemotherapy Advanced Breast Cancer
researchProduct

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

2021

Abstract Purpose Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2): TNBC accounts for approximately 20% of newly diagnosed breast cancers and is associated with younger age at diagnosis, greater recurrence risk and shorter survival time. Therapeutic options are very scarce. Aim of the present analysis is to provide further insights into the clinical activity of metronomic chemotherapy (mCHT), in a real-life setting. Methods We used data included in the VICTOR-6 study for the present analysis. VICTOR-6 is an Italian multicentre retrosp…

OncologyCancer Researchmedicine.medical_specialtyReceptor ErbB-2Breast NeoplasmsTriple Negative Breast NeoplasmsVinorelbineCapecitabine; Cyclophosphamide; Methotrexate; Metronomic chemotherapy; Triple-negative breast cancer; Vinorelbine; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cyclophosphamide; Female; Humans; Receptor ErbB-2; Retrospective Studies; Breast Neoplasms; Triple Negative Breast NeoplasmsCapecitabineErbB-2Breast cancerTriple-negative breast cancerRetrospective StudieInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalCyclophosphamideTriple-negative breast cancerCapecitabineRetrospective StudiesAntineoplastic Combined Chemotherapy Protocolbusiness.industryMetronomic chemotherapyVinorelbinemedicine.diseaseClinical TrialMetronomic ChemotherapyMetastatic breast cancerRegimenMethotrexateOncologyFemalebusinessBreast NeoplasmHumanReceptormedicine.drug
researchProduct

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

2019

Abstract Background The 8th edition of the American Joint Committee on Cancer (AJCC) staging has introduced prognostic stage based on anatomic stage combined with biologic factors. We aimed to validate the prognostic stage in HER2-positive breast cancer patients enrolled in the ShortHER trial. Methods The ShortHER trial randomized 1253 HER2-positive patients to 9 weeks or 1 year of adjuvant trastuzumab combined with chemotherapy. Patients were classified according to the anatomic and the prognostic stage. Distant disease-free survival (DDFS) was calculated from randomization to distant relapse or death. Results A total of 1244 patients were included. Compared to anatomic stage, the prognost…

OncologySettore MED/06 - Oncologia Medicamedicine.medical_treatmentlcsh:MedicineAntineoplastic Agents Immunological0302 clinical medicineBreast cancerTrastuzumabAntineoplastic Combined Chemotherapy Protocols8th AJCC030212 general & internal medicineStage (cooking)8th AJCC; Breast cancer; HER2-positive; Prognostic stage; TrastuzumabGeneral MedicineMiddle AgedPrognosisImmunologicalLocal030220 oncology & carcinogenesisFemaleResearch Articlemedicine.drugAdultmedicine.medical_specialtyRandomizationSocio-culturaleAntineoplastic AgentsBreast NeoplasmsDisease-Free Survival03 medical and health sciencesBreast cancerInternal medicinePrognostic stagemedicineAdjuvant therapyHumanserbB-2AgedNeoplasm StagingCancer stagingChemotherapybusiness.industrylcsh:RCancerGenes erbB-2Trastuzumabmedicine.diseaseHER2-positive Breast cancer Trastuzumab Prognostic stage 8th AJCCHER2-positiveNeoplasm RecurrenceGenesNeoplasm Recurrence Localbusiness
researchProduct

Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): What has changed over the time? Preliminary results of the VIC…

2017

e12552 Background: mCHT is the minimum biologically effective dose of a chemotherapeutic agent, given at regular dosing regimen with no prolonged drug free interval, that leads to anti-tumor activity. Old regimens included Cyclophosphamide-Methotrexate (CM), whereas in the last years new regimens, such as Vinorelbine (VRL) and Capecitabine (CAPE)-based have been developed. Aim of this observational retrospective ongoing study is to describe the use of mCHT in ABC pts across 5 years and the clinical characteristics of the pts together with efficacy of old (CM-like) vs new (VRL/CAPE-based) metronomic regimens in terms of response and disease control. Methods: We retrospectively identified fr…

0301 basic medicineOncologyDrugCancer Researchmedicine.medical_specialtybusiness.industryAdvanced breastmedia_common.quotation_subjectDosing regimenCancermedicine.diseaseEffective dose (pharmacology)Metronomic ChemotherapyFree intervalSurgery03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinemedicineMetronomic chemotherapy advanced breast cancerbusinessmedia_common
researchProduct

MOESM1 of Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

2019

Additional file 1. Summary of details of studies aimed at evaluating the American Joint Committee on Cancer (AJCC) 8th edition breast cancer prognostic staging.

researchProduct